ASSEMBLY BIOSCIENCES INC (ASMB)
Health Care · Clinical-stage antiviral therapeutics · NASDAQ
Assembly Biosciences develops next-generation antivirals targeting herpes and hepatitis viruses, with a portfolio advancing through clinical trials and now powered by a Gilead partnership licensing its genital herpes program.
What ASSEMBLY BIOSCIENCES INC does
Assembly Biosciences is a biotechnology company developing innovative therapeutics targeting serious viral diseases including recurrent genital herpes, hepatitis delta virus (HDV), hepatitis B virus (HBV), and transplant-related herpesviruses. The company is advancing multiple clinical-stage investigational therapies through partnerships and internal development, most notably through a 2025 collaboration with Gilead Sciences in which Gilead exercised an option to license Assembly's helicase-primase inhibitor program for recurrent genital herpes treatment.
Themes: ["Antiviral therapeutics","Herpes simplex virus (HSV) treatment","Viral helicase-primase inhibitors","Hepatitis B and D treatment","Clinical-stage drug development"]
Fundamentals
- Price$27.87 as of 2026-07-09 close
- Market cap$551M as of 2026-07-10
- 1-year return+48.9% as of 2026-07-09 close
- Net margin-9.0% as of 2026-07-10
- ROE-4.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+121.1% as of 2026-07-10
- Beta1.08 as of 2026-07-10
Key risks (from latest filing)
["Dependence on the Gilead Sciences collaboration for the HPI program — financial success depends on Gilead's commitment and the ability to realize anticipated financial benefits from the partnership","Clinical development risk — safety and efficacy data from ongoing studies may not warrant further development of product candidates or may fail to differentiate them from competitors","Funding and cash runway — the company is currently unprofitable and must secure additional capital to continue research, clinical studies, and business operations"]
Competitors & peers
- Gilead Sciences (GILD)
- Merck (MRK)
- Vertex Pharmaceuticals (VERX)
- Intercept Pharmaceuticals (ICPT)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.